KR101017732B1 - 내재화 항-ｃｄ74 항체 및 그 이용방법 - Google Patents

내재화 항-ｃｄ74 항체 및 그 이용방법 Download PDF

Info

Publication number
KR101017732B1
KR101017732B1 KR1020047013665A KR20047013665A KR101017732B1 KR 101017732 B1 KR101017732 B1 KR 101017732B1 KR 1020047013665 A KR1020047013665 A KR 1020047013665A KR 20047013665 A KR20047013665 A KR 20047013665A KR 101017732 B1 KR101017732 B1 KR 101017732B1
Authority
KR
South Korea
Prior art keywords
antibody
delete delete
fragment
human
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020047013665A
Other languages
English (en)
Korean (ko)
Other versions
KR20040089695A (ko
Inventor
한스 한센
슈-온 륭
젱싱 큐
데이비드 엠. 골든베르그
Original Assignee
이뮤노메딕스, 인코오포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27788972&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101017732(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 이뮤노메딕스, 인코오포레이티드 filed Critical 이뮤노메딕스, 인코오포레이티드
Publication of KR20040089695A publication Critical patent/KR20040089695A/ko
Application granted granted Critical
Publication of KR101017732B1 publication Critical patent/KR101017732B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Optics & Photonics (AREA)
  • Emergency Medicine (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
KR1020047013665A 2002-03-01 2003-03-03 내재화 항-ｃｄ74 항체 및 그 이용방법 Expired - Lifetime KR101017732B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36025902P 2002-03-01 2002-03-01
US60/360,259 2002-03-01
PCT/GB2003/000890 WO2003074567A2 (en) 2002-03-01 2003-03-03 Internalizing anti-cd74 antibodies and methods of use

Publications (2)

Publication Number Publication Date
KR20040089695A KR20040089695A (ko) 2004-10-21
KR101017732B1 true KR101017732B1 (ko) 2011-02-28

Family

ID=27788972

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020047013665A Expired - Lifetime KR101017732B1 (ko) 2002-03-01 2003-03-03 내재화 항-ｃｄ74 항체 및 그 이용방법

Country Status (13)

Country Link
US (8) US7312318B2 (enExample)
EP (3) EP1483294B2 (enExample)
JP (2) JP4472351B2 (enExample)
KR (1) KR101017732B1 (enExample)
CN (2) CN1649902B (enExample)
AT (1) ATE477276T1 (enExample)
AU (2) AU2003215732B2 (enExample)
CA (1) CA2478012C (enExample)
DE (1) DE60333732D1 (enExample)
DK (1) DK1483294T3 (enExample)
ES (1) ES2350477T5 (enExample)
IL (2) IL163851A0 (enExample)
WO (1) WO2003074567A2 (enExample)

Families Citing this family (182)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0757213A (ja) * 1993-08-13 1995-03-03 Matsushita Electric Ind Co Ltd 磁気ヘッド
US6183744B1 (en) * 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US7829064B2 (en) * 1999-05-10 2010-11-09 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods
US8383081B2 (en) * 1999-05-10 2013-02-26 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods of use
HK1046635B (en) * 1999-06-09 2009-10-09 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target b-cells
US20110045005A1 (en) 2001-10-19 2011-02-24 Craig Crowley Compositions and methods for the treatment of tumor of hematopoietic origin
US7591994B2 (en) 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US8435529B2 (en) 2002-06-14 2013-05-07 Immunomedics, Inc. Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
US20160279239A1 (en) * 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
US8361464B2 (en) 2002-03-01 2013-01-29 Immunomedics, Inc. Anthracycline-Antibody Conjugates for Cancer Therapy
EP1483294B2 (en) * 2002-03-01 2019-10-30 Immunomedics, Inc. Internalizing anti-cd74 antibodies and methods of use
US7906118B2 (en) 2005-04-06 2011-03-15 Ibc Pharmaceuticals, Inc. Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology
EP1546412B1 (en) 2002-10-02 2014-05-21 California Institute Of Technology Microfluidic nucleic acid analysis
AU2003288467A1 (en) * 2002-12-13 2004-07-09 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
US8420086B2 (en) 2002-12-13 2013-04-16 Immunomedics, Inc. Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
US7534427B2 (en) * 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
US20040202666A1 (en) * 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
JP4874090B2 (ja) * 2003-01-31 2012-02-08 イミューノメディクス、インコーポレイテッド 治療薬および診断薬を投与するための方法および組成物
KR100930353B1 (ko) 2003-03-06 2009-12-08 엘지전자 주식회사 디스크 플레이어의 접속요청 처리방법
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
CA2534898A1 (en) * 2003-08-08 2005-02-17 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells
US20060228331A1 (en) 2003-10-10 2006-10-12 Novo Nordisk A/S IL-21 Derivatives and variants
EP1680138B1 (en) * 2003-10-17 2013-07-17 Novo Nordisk A/S Combination therapy
ES2472690T3 (es) * 2003-11-17 2014-07-02 Genentech, Inc. Anticuerpo contra CD22 para el tratamiento de tumores de origen hematopoy�tico
US9481878B2 (en) 2004-02-13 2016-11-01 Immunomedics, Inc. Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
US20110064754A1 (en) * 2005-03-03 2011-03-17 Center For Molecular Medicine And Immunology Immunoconjugates Comprising Poxvirus-Derived Peptides and Antibodies Against Antigen-Presenting Cells for Subunit-Based Poxvirus Vaccines
US9550838B2 (en) 2004-02-13 2017-01-24 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US8491914B2 (en) * 2004-02-13 2013-07-23 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for delivery of interference RNA
US8652484B2 (en) 2004-02-13 2014-02-18 Immunomedics, Inc. Delivery system for cytotoxic drugs by bispecific antibody pretargeting
US8435539B2 (en) * 2004-02-13 2013-05-07 Immunomedics, Inc. Delivery system for cytotoxic drugs by bispecific antibody pretargeting
US8562988B2 (en) * 2005-10-19 2013-10-22 Ibc Pharmaceuticals, Inc. Strategies for improved cancer vaccines
US8883160B2 (en) * 2004-02-13 2014-11-11 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US8551480B2 (en) 2004-02-13 2013-10-08 Immunomedics, Inc. Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
US20110020273A1 (en) * 2005-04-06 2011-01-27 Ibc Pharmaceuticals, Inc. Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof
US7589063B2 (en) 2004-12-14 2009-09-15 Aplagen Gmbh Molecules which promote hematopoiesis
BRPI0607486B8 (pt) 2005-03-03 2021-05-25 Immunomedics Inc anticorpo humanizado l243 contra hla-dr presente nas células hladr+,composição farmacêutica, kit e uso dos referidos anticorpos.
US10058621B2 (en) 2015-06-25 2018-08-28 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
JP2006248978A (ja) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
US8475794B2 (en) 2005-04-06 2013-07-02 Ibc Pharmaceuticals, Inc. Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
US8349332B2 (en) 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
WO2006114115A1 (de) 2005-04-26 2006-11-02 Trion Pharma Gmbh Kombination von antikörpern mit glukokortikoiden zur behandlung von krebs
JP5065253B2 (ja) * 2005-05-06 2012-10-31 ザイモジェネティクス， インコーポレイテッド Ｉｌ−３１モノクローナル抗体とその使用法
WO2007101698A2 (en) * 2006-03-09 2007-09-13 Aplagen Gmbh Modified molecules which promote hematopoiesis
RS54163B1 (sr) 2006-05-30 2015-12-31 Genentech Inc. Anti-cd22 antitela, njihovi imunokonjugati i njihova upotreba
BRPI0717902A2 (pt) 2006-12-01 2013-10-29 Medarex Inc "anticorpo monoclonal humano isolado, composição, conjugado anticorpo-molécula parceria, imunoconjugado, molécula de ácido nucléico isolada, vetor de expressão, célula hospedeira, método para prepar um anticorpo anti-cd22, método para inibir o desenvolvimento de uma célula tumoral que expressa cd22 e método para tratar uma doença inflamatória ou autoimuneem um indivíduo"
US20090175838A1 (en) * 2007-01-26 2009-07-09 Newell Rogers M Karen Methods of modulating immune function
CN106432496B (zh) 2007-07-16 2020-02-07 健泰科生物技术公司 抗cd79b抗体和免疫偶联物及使用方法
AR067543A1 (es) 2007-07-16 2009-10-14 Genentech Inc Anticuerpos anti-cd79b e inmunoconjugados humanizados y metodos de uso
WO2009055005A2 (en) 2007-10-23 2009-04-30 The Regents Of The University Of Colorado Competitive inhibitors of invariant chain expression and/or ectopic clip binding
US9078864B2 (en) 2008-01-08 2015-07-14 Akthelia Pharmaceuticals Agonists for antimicrobial peptide systems
US11072655B2 (en) 2008-01-15 2021-07-27 The Board Of Trustees Of The Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
DK3056515T4 (da) 2008-01-15 2025-10-20 Univ Leland Stanford Junior Fremgangsmåde til at manipulere fagocytose medieret af cd47
ES2988620T3 (es) 2008-01-15 2024-11-21 The Board Of Trustees Of The Leland Stanfordjunior Univ Marcadores de las células madre de la leucemia mieloide aguda
EP2247620B1 (en) 2008-01-31 2016-05-18 Genentech, Inc. Anti-cd79b antibodies and immunoconjugates and methods of use
KR20110014141A (ko) * 2008-03-20 2011-02-10 카롤러스 테라퓨틱스, 인코포레이티드 염증을 치료하는 방법
US20110070184A1 (en) * 2008-03-24 2011-03-24 Carolus Therpeutics, Inc. Methods and compositions for treating atherosclerosis and related condidtions
CA2734265C (en) * 2008-08-20 2017-12-19 Ibc Pharmaceuticals, Inc. Dock-and-lock (dnl) vaccines for cancer therapy
WO2010056910A2 (en) * 2008-11-12 2010-05-20 Carolus Therapeutics, Inc. Methods of treating cardiovascular disorders
HRP20170908T1 (hr) 2008-12-09 2017-09-22 F. Hoffmann - La Roche Ag Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice
EP2198879A1 (en) * 2008-12-11 2010-06-23 Institut Curie CD74 modulator agent for regulating dendritic cell migration and device for studying the motility capacity of a cell
PL3939617T3 (pl) 2009-02-13 2025-03-17 Immunomedics, Inc. Związki pośrednie do wytwarzania koniugatów z wiązaniem rozszczepialnym wewnątrzkomórkowo
CN102482701B (zh) 2009-09-16 2015-05-13 免疫医疗公司 I类抗-cea抗体及其使用
MX2012003514A (es) * 2009-09-23 2012-04-19 Carolus Therapeutics Inc Metodos para tratamiento de inflamaciones.
IN2012DN02692A (enExample) 2009-11-05 2015-09-04 Ct Molecular Med & Immunology
WO2011068845A1 (en) 2009-12-02 2011-06-09 Immunomedics, Inc. Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
WO2011085354A1 (en) * 2010-01-11 2011-07-14 Center For Molecular Medicine And Immunology Enhanced cytotoxicity of anti-cd74 and anti-hla-dr antibodies with interferon-gamma
AU2011235328A1 (en) * 2010-04-01 2012-09-27 Immunomedics, Inc. Antibody-based depletion of antigen-presenting cells and dendritic cells
DE102010026064A1 (de) * 2010-06-30 2012-01-05 Siemens Aktiengesellschaft 11C-markiertes Peptid zur Detektion eines krankhaften Gewebes
DE102010026063A1 (de) * 2010-06-30 2012-01-05 Siemens Aktiengesellschaft 11C-markiertes Peptid zur Detektion eines krankhaften Gewebes
EP2605788B1 (en) * 2010-08-17 2018-10-10 IBC Pharmaceuticals, Inc. Combination therapy with anti-cd74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases
EP2611464B1 (en) 2010-09-03 2018-04-25 AbbVie Stemcentrx LLC Novel modulators and methods of use
WO2012094495A2 (en) 2011-01-05 2012-07-12 The Texas A&M University System Clip modulation for the treatment of mucosal diseases
CN103458930B (zh) * 2011-02-01 2019-10-15 健玛保 针对cd74的人抗体和抗体-药物缀合物
US8673308B2 (en) * 2011-02-23 2014-03-18 Als Therapy Development Institute Targeting of CD8+ T-lymphocytes to treat neurodegenerative diseases
WO2012151199A1 (en) 2011-05-02 2012-11-08 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
WO2013012894A1 (en) 2011-07-18 2013-01-24 The Ohio State University Fty720 increases cd74 expression and sensitizes cancer cells to anti-cd74 antibody-mediated cell death
EP4530630A3 (en) 2011-10-26 2025-06-18 Elanco Tiergesundheit AG Monoclonal antibodies and methods of use
WO2013059885A2 (en) 2011-10-28 2013-05-02 Cephalon Australia Pty Ltd Polypeptide constructs and uses thereof
US9192664B2 (en) 2011-12-05 2015-11-24 Immunomedics, Inc. Therapeutic use of anti-CD22 antibodies for inducing trogocytosis
US9757458B2 (en) 2011-12-05 2017-09-12 Immunomedics, Inc. Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
CA2873402C (en) 2012-05-15 2023-10-24 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
AU2013274078A1 (en) 2012-06-14 2015-01-29 Ambrx, Inc. Anti-PSMA antibodies conjugated to nuclear receptor ligand polypeptides
US9382329B2 (en) 2012-08-14 2016-07-05 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
US20150231241A1 (en) 2012-08-14 2015-08-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
AU2013302696B9 (en) 2012-08-14 2018-08-09 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
GB201216649D0 (en) * 2012-09-18 2012-10-31 Univ Birmingham Agents and methods
JP6273205B2 (ja) 2012-10-05 2018-01-31 協和発酵キリン株式会社 ヘテロダイマータンパク質組成物
AU2013328580B2 (en) 2012-10-12 2016-01-21 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US10206918B2 (en) 2012-12-13 2019-02-19 Immunomedics, Inc. Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
BR112015013444B1 (pt) 2012-12-13 2022-11-01 Immunomedics, Inc Uso de um imunoconjugado
US20240148873A1 (en) 2012-12-13 2024-05-09 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
US12310958B2 (en) 2012-12-13 2025-05-27 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US9931417B2 (en) 2012-12-13 2018-04-03 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US10413539B2 (en) 2012-12-13 2019-09-17 Immunomedics, Inc. Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
US10137196B2 (en) 2012-12-13 2018-11-27 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
ES2819573T3 (es) 2012-12-13 2021-04-16 Immunomedics Inc Método para producir inmunoconjugados de anticuerpo-SN-38 con un enlazador CL2A
US9492566B2 (en) 2012-12-13 2016-11-15 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US10744129B2 (en) 2012-12-13 2020-08-18 Immunomedics, Inc. Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
CN105209068A (zh) 2013-02-07 2015-12-30 免疫医疗公司 用于靶向癌症治疗的缀合至抗体的高效2-吡咯啉多柔比星的前药形式(p2pdox)
WO2014127200A1 (en) 2013-02-15 2014-08-21 Immunomedics, Inc. Chimeric and humanized anti-histone antibodies
EP2774930A1 (en) 2013-03-07 2014-09-10 Aptenia S.R.L. Metallocene compounds and labeled molecules comprising the same for in vivo imaging.
US20140271462A1 (en) 2013-03-13 2014-09-18 Imaginab, Inc. Antigen binding constructs to cd8
MX362970B (es) 2013-03-13 2019-02-28 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas.
CN103207277B (zh) * 2013-03-28 2015-04-15 中国人民解放军第二军医大学 一种人源性可溶型cd74蛋白的elisa检测试剂盒及检测方法
EP2992013B1 (en) 2013-04-29 2019-12-04 Teva Pharmaceuticals Australia Pty Ltd Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
US11253606B2 (en) 2013-07-23 2022-02-22 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
WO2015067277A1 (en) 2013-11-07 2015-05-14 University Of Copenhagen Timp-1 binding partner
KR102088169B1 (ko) * 2013-12-25 2020-03-12 다이이찌 산쿄 가부시키가이샤 항 trop2 항체-약물 컨쥬게이트
KR102500408B1 (ko) 2014-01-27 2023-02-16 몰레큘러 템플레이츠, 인코퍼레이션. 포유류에 적용하기 위한 탈면역된 시가 독소 a 서브유닛 작동체 폴리펩티드
ES2978993T3 (es) 2014-02-21 2024-09-23 Ibc Pharmaceuticals Inc Terapia de enfermedades mediante la inducción de la respuesta inmunitaria a las células que expresan Trop-2
CN106029098A (zh) 2014-02-25 2016-10-12 免疫医疗公司 人源化rfb4抗cd22抗体
PL3604333T3 (pl) * 2014-03-11 2021-11-08 Molecular Templates, Inc. Białka zawierające regiony efektorowe podjednostki a toksyny shiga proksymalnie do końca aminowego oraz celujące w komórki regiony wiążące typu immunoglobuliny zdolne do swoistego wiązania cd38
CN112759650B (zh) 2014-04-03 2024-10-01 Igm生物科学股份有限公司 修饰的j链
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
US10351621B2 (en) 2014-06-24 2019-07-16 Immunomedics, Inc. Anti-histone therapy in acute kidney injury
WO2015200260A1 (en) 2014-06-24 2015-12-30 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
WO2016037985A1 (en) 2014-09-08 2016-03-17 Ruprecht-Karls-Universität Heidelberg Construct for the delivery of a molecule into the cytoplasm of a cell
CN106687141A (zh) 2014-09-10 2017-05-17 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其缀合物
CN104280553B (zh) * 2014-09-22 2016-06-08 中国人民解放军第二军医大学 一种小鼠源性可溶型cd74蛋白的elisa检测试剂盒及检测方法
SI3262071T1 (sl) 2014-09-23 2020-07-31 F. Hoffmann-La Roche Ag Način uporabe imunokonjugatov proti CD79b
CA2961774C (en) 2014-10-07 2023-05-23 Immunomedics, Inc. Neoadjuvant use of antibody-drug conjugates
IL251822B2 (en) 2014-10-29 2023-03-01 Teva Pharmaceuticals Australia Pty Ltd Variants of interferon alpha-2-b
JP6858128B2 (ja) 2015-02-18 2021-04-14 エンリヴェックス セラピューティクス リミテッド 癌治療のための免疫療法とサイトカイン制御療法との組み合わせ
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
KR20170116039A (ko) * 2015-02-18 2017-10-18 에프. 호프만-라 로슈 아게 표적 세포에 대항하여 t 세포 세포독성을 특이적으로 유도하기 위한 면역컨주게이트
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
SI3265575T1 (sl) 2015-03-04 2021-08-31 Igm Biosciences, Inc. Vezne molekule CD20 in njihove uporabe
CN113106053A (zh) 2015-04-21 2021-07-13 恩立夫克治疗有限责任公司 治疗性汇集的血液凋亡细胞制剂与其用途
AU2016252771B2 (en) 2015-04-22 2021-12-16 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells
CN107849096B (zh) 2015-05-30 2022-05-24 分子模板公司 去免疫化的志贺毒素a亚基支架和包含它们的细胞靶向分子
GB201511191D0 (en) * 2015-06-25 2015-08-12 Immatics Biotechnologies Gmbh T-cell epitopes for the immunotherapy of myeloma
PT3313443T (pt) 2015-06-25 2023-08-30 Immunomedics Inc Combinação de anticorpos anti-hla-dr ou anti-trop-2 com inibidores de microtúbulos, inibidores de parp, inibidores de bruton quinase ou inibidores de fosfoinositídeo 3-quinase melhora significativamente o resultado terapêutico no cancro
US10195175B2 (en) 2015-06-25 2019-02-05 Immunomedics, Inc. Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
EP3316885B1 (en) 2015-07-01 2021-06-23 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
CN115960230A (zh) 2015-08-07 2023-04-14 伊麦吉纳博公司 靶向分子的抗原结合构建体
EP3356401B1 (en) 2015-09-30 2020-06-24 IGM Biosciences, Inc. Binding molecules with modified j-chain
ES2996834T3 (en) 2015-09-30 2025-02-13 Igm Biosciences Inc Binding molecules with modified j-chain
EP3359194A4 (en) 2015-10-06 2019-04-24 Merck Sharp & Dohme Corp. ANTIBODY-ACTIVE CONJUGATE FOR ANTI-INFLAMMATORY APPLICATIONS
AU2016370813A1 (en) * 2015-12-18 2018-06-28 Novartis Ag Antibodies targeting CD32b and methods of use thereof
US10869929B2 (en) 2016-01-29 2020-12-22 Merck Sharp & Dohme Corp. Phosphonate linkers and their use to facilitate cellular retention of compounds
EP3413914A4 (en) 2016-02-10 2019-10-16 Immunomedics, Inc. COMBINATION OF ABCG2 INHIBITORS WITH SACITUZUMAB GOVITECAN (IMMU-132) TO OVERCOME THE RESISTANCE TO SN-38 IN TROP-2-EXPRESSIVE CANCER
EP3416661A4 (en) 2016-02-18 2020-03-04 Enlivex Therapeutics Ltd. COMBINATION OF IMMUNOTHERAPY AND CYTOKINE CONTROL THERAPY FOR THE TREATMENT OF CANCER
AU2017257254B2 (en) 2016-04-27 2022-02-24 Immunomedics, Inc. Efficacy of anti-Trop-2-SN-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors
CN109804246B (zh) * 2016-08-01 2022-05-17 健康研究公司 用于快速克隆t细胞受体的组合物和方法
WO2018069289A1 (en) 2016-10-11 2018-04-19 Medimmune Limited Antibody-drug conjugates with immune-mediated therapy agents
CN114773439A (zh) 2016-12-07 2022-07-22 分子模板公司 用于位点特异性缀合的志贺毒素a亚基效应子多肽、志贺毒素效应子支架和细胞靶向分子
MX2019008840A (es) 2017-01-25 2019-09-09 Molecular Templates Inc Moleculas con direccion hacia las celulas que comprenden efectores de la sub-unidad a de la toxina shiga desinmunizados y epitopos de las celulas t cd8+.
JP2020512314A (ja) 2017-03-27 2020-04-23 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． サシツズマブゴビテカンとＲＡＤ５１阻害剤を用いたＴｒｏｐ−２発現トリプルネガティブ乳癌の治療
EP3606964A4 (en) 2017-04-03 2020-12-09 Immunomedics, Inc. SUBCUTANE ADMINISTRATION OF ANTIBODY DRUG CONJUGATES FOR CANCER THERAPY
US12006354B2 (en) * 2017-05-24 2024-06-11 Novartis Ag Antibody-IL2 engrafted proteins and methods of use in the treatment of cancer
SG11202010469QA (en) 2018-05-23 2020-11-27 Adc Therapeutics Sa Molecular adjuvant
WO2020064847A1 (en) 2018-09-26 2020-04-02 Ascendis Pharma A/S Degradable hyaluronic acid hydrogels
CN111303293B (zh) * 2018-11-14 2022-08-30 杭州尚健生物技术有限公司 一种融合蛋白及其用途
TW202100184A (zh) * 2019-05-20 2021-01-01 瑞士商諾華公司 Mcl-1抑制劑抗體－藥物結合物及使用方法
EP4058479A4 (en) 2019-11-15 2024-02-28 University of Tennessee Research Foundation MODIFIED IMMUNOLOBULINES FOR TARGETING AMYLOID DEPOSITS
EP4178624A2 (en) 2020-07-07 2023-05-17 Bionecure Therapeutics, Inc. Maytansinoids as adc payloads and their use for the treatment of cancer
US20230181471A1 (en) 2020-07-09 2023-06-15 Hoffmann-La Roche Inc. Concentrated compositions of proteins, their preparation and use thereof
JP2023545099A (ja) 2020-10-08 2023-10-26 アフィメド ゲーエムベーハー 三重特異性バインダー
WO2022079211A1 (en) 2020-10-16 2022-04-21 Adc Therapeutics Sa Glycoconjugates
CN116635064A (zh) 2020-12-18 2023-08-22 世纪治疗股份有限公司 具有适应性受体特异性的嵌合抗原受体系统
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
JPWO2022239720A1 (enExample) 2021-05-10 2022-11-17
CN117915949A (zh) 2021-05-18 2024-04-19 田纳西大学研究基金会 用于治疗淀粉样蛋白病症的抗体-肽融合蛋白
CN113238061B (zh) * 2021-07-09 2021-10-01 中南大学湘雅医院 以cd180阴性b细胞指示重症肌无力病情的试剂盒及应用
JP2024529381A (ja) 2021-07-30 2024-08-06 アフィメド ゲーエムベーハー デュプレックスボディ
CN118043080A (zh) 2021-08-13 2024-05-14 昆山新蕴达生物科技有限公司 一种基于微管抑制剂的抗体偶联药物
US20240392033A1 (en) 2021-08-24 2024-11-28 Kunshan Xinyunda Biotech Co., Ltd. Antibody-drug conjugate conjugated via breakable linker
EP4426727A2 (en) 2021-11-03 2024-09-11 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
EP4426439A1 (en) 2021-11-03 2024-09-11 Affimed GmbH Bispecific cd16a binders
JP2024545138A (ja) 2021-12-09 2024-12-05 クンシャン シンユンター バイオテック カンパニー，リミティド 親和性が改善された抗体薬物複合体、その調製法、及びその応用
EP4525927A1 (en) 2022-05-20 2025-03-26 Novartis AG Antibody-drug conjugates of antineoplastic compounds and methods of use thereof
TW202412843A (zh) 2022-08-10 2024-04-01 日商興和股份有限公司 新藥物複合體
CN116139267A (zh) * 2023-01-28 2023-05-23 华中科技大学同济医学院附属同济医院 小鼠cd74单克隆抗体在制备治疗肿瘤药物中的应用
WO2025250969A1 (en) * 2024-05-31 2025-12-04 Vertex Pharmaceuticals Incorporated Anti-cd74 antibodies, conjugates and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998050435A1 (en) * 1997-05-02 1998-11-12 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Immunotoxins, comprising an onc protein, directed against malignant cells
WO2000067795A1 (en) * 1999-05-10 2000-11-16 Immunomedics, Inc. Immunotherapy of b-cell malignancies using anti-cd22 antibodies
WO2000074718A1 (en) * 1999-06-09 2000-12-14 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target b-cells

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1541435A (en) 1975-02-04 1979-02-28 Searle & Co Immunological materials
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US5204095A (en) 1980-04-09 1993-04-20 National Research Development Corporation Monoclonal antibodies against hepatitis B virus
US4916213A (en) 1983-02-22 1990-04-10 Xoma Corporation Ribosomal inhibiting protein-immunoglobulin conjugates with specificity for tumor cell surface antigens, and mixtures thereof
US4925922A (en) 1983-02-22 1990-05-15 Xoma Corporation Potentiation of cytotoxic conjugates
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US4824659A (en) 1985-06-07 1989-04-25 Immunomedics, Inc. Antibody conjugates
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US4918163A (en) 1985-09-27 1990-04-17 Pfizer Inc. Monoclonal antibodies specific for lipid-A determinants of gram negative bacteria
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5258498A (en) * 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5846534A (en) * 1988-02-12 1998-12-08 British Technology Group Limited Antibodies to the antigen campath-1
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5134075A (en) 1989-02-17 1992-07-28 Oncogen Limited Partnership Monoclonal antibody to novel antigen associated with human tumors
US5171665A (en) 1989-04-17 1992-12-15 Oncogen Monoclonal antibody to novel antigen associated with human tumors
JPH02283294A (ja) 1989-04-24 1990-11-20 Sumitomo Chem Co Ltd ヒトモノクローナル抗体
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5665595A (en) * 1991-06-07 1997-09-09 Dowelanco Immunoglobulins against insect tissue
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5686072A (en) * 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
EP1005870B1 (en) * 1992-11-13 2009-01-21 Biogen Idec Inc. Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US6645493B1 (en) * 1993-05-17 2003-11-11 The Picower Institute For Medical Research Composition containing anti-MIF antibody
US5484892A (en) * 1993-05-21 1996-01-16 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells
US6084067A (en) * 1993-07-26 2000-07-04 Dana-Farber Cancer Institute CTLA4/CD28 ligands and uses therefor
US5417972A (en) * 1993-08-02 1995-05-23 The Board Of Trustees Of The Leland Stanford Junior University Method of killing B-cells in a complement independent and an ADCC independent manner using antibodies which specifically bind CDIM
US5443953A (en) 1993-12-08 1995-08-22 Immunomedics, Inc. Preparation and use of immunoconjugates
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
IL114909A (en) 1994-08-12 1999-10-28 Immunomedics Inc Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
US5874540A (en) 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
US5728369A (en) * 1994-10-05 1998-03-17 Immunomedics, Inc. Radioactive phosphorus labeling of proteins for targeted radiotherapy
US5798554A (en) 1995-02-24 1998-08-25 Consorzio Per La Ricerca Sulla Microelettronica Nel Mezzogiorno MOS-technology power device integrated structure and manufacturing process thereof
AUPO591797A0 (en) * 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
US6254868B1 (en) 1996-03-20 2001-07-03 Immunomedics, Inc. Glycosylated humanized B-cell specific antibodies
JP2000510119A (ja) 1996-05-03 2000-08-08 イムノメディクス，インコーポレイテッド ガンに対する標的コンビネーション免疫療法
US7521531B2 (en) * 1996-08-28 2009-04-21 Immunomedics, Inc. Methods for the purification of stable radioiodine conjugates
US6653104B2 (en) * 1996-10-17 2003-11-25 Immunomedics, Inc. Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells
US6051228A (en) * 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
EP1135498B1 (en) 1998-11-18 2008-01-23 Genentech, Inc. Antibody variants with higher binding affinity compared to parent antibodies
WO2000063403A2 (en) 1999-04-15 2000-10-26 Crucell Holland B.V. Recombinant protein production in a human cell using sequences encoding adenovirus e1 protein
AU777970C (en) * 1999-05-07 2006-08-17 F. Hoffman-La Roche Ag Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
US7829064B2 (en) * 1999-05-10 2010-11-09 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods
US7527787B2 (en) * 2005-10-19 2009-05-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
US7534866B2 (en) * 2005-10-19 2009-05-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
US8383081B2 (en) * 1999-05-10 2013-02-26 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods of use
US6629995B1 (en) * 2000-03-31 2003-10-07 Super Gen, Inc. Camptothecin conjugates
KR20020091170A (ko) * 2000-03-31 2002-12-05 아이덱 파마슈티칼즈 코포레이션 Ｂ 세포 림프종의 치료를 위한 항-사이토카인 항체 또는길항제 및 항-ｃｄ２０의 조합된 사용
CA2411102A1 (en) * 2000-06-20 2001-12-27 Idec Pharmaceutical Corporation Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
PL375139A1 (en) * 2001-01-26 2005-11-28 Emory University Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
AU2002255961B2 (en) * 2001-03-29 2007-08-23 Baxalta GmbH Methods and compositions for using MHC class II invariant chain polypeptide as a receptor for macrophage migration inhibitory factor
US8287864B2 (en) * 2002-02-14 2012-10-16 Immunomedics, Inc. Structural variants of antibodies for improved therapeutic characteristics
US7591994B2 (en) * 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
EP1483294B2 (en) * 2002-03-01 2019-10-30 Immunomedics, Inc. Internalizing anti-cd74 antibodies and methods of use
US8361464B2 (en) * 2002-03-01 2013-01-29 Immunomedics, Inc. Anthracycline-Antibody Conjugates for Cancer Therapy
US7563433B2 (en) * 2007-01-11 2009-07-21 Immunomedics, Inc. Methods and compositions for F-18 labeling of proteins, peptides and other molecules
AU2003288467A1 (en) * 2002-12-13 2004-07-09 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
JP4874090B2 (ja) * 2003-01-31 2012-02-08 イミューノメディクス、インコーポレイテッド 治療薬および診断薬を投与するための方法および組成物
CN101484182B (zh) * 2005-04-06 2014-06-11 Ibc药品公司 由同二聚体、同四聚体或二聚体的二聚体组成的稳定连接复合体的生产方法及用途
US8067006B2 (en) * 2005-04-06 2011-11-29 Immunomedics, Inc. Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
CA2734265C (en) * 2008-08-20 2017-12-19 Ibc Pharmaceuticals, Inc. Dock-and-lock (dnl) vaccines for cancer therapy
KR102188537B1 (ko) 2019-08-14 2020-12-08 라인플러스 주식회사 유니캐스트 및 멀티캐스트를 이용한 그룹 통화 방법 및 시스템

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998050435A1 (en) * 1997-05-02 1998-11-12 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Immunotoxins, comprising an onc protein, directed against malignant cells
WO2000067795A1 (en) * 1999-05-10 2000-11-16 Immunomedics, Inc. Immunotherapy of b-cell malignancies using anti-cd22 antibodies
WO2000074718A1 (en) * 1999-06-09 2000-12-14 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target b-cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
A COMPANION TO METHODS IN ENZYMOLOGY, ACADEMIC PRESS INC., NEW YORK,NY,US,Vol.8,1995,pages 83-93

Also Published As

Publication number Publication date
DE60333732D1 (de) 2010-09-23
JP4472351B2 (ja) 2010-06-02
KR20040089695A (ko) 2004-10-21
US7312318B2 (en) 2007-12-25
AU2003215732A1 (en) 2003-09-16
EP2865688A1 (en) 2015-04-29
US20040115193A1 (en) 2004-06-17
ES2350477T3 (es) 2011-01-24
CN102174108A (zh) 2011-09-07
IL163851A (en) 2010-11-30
EP2308898B1 (en) 2016-06-08
US7931903B2 (en) 2011-04-26
EP1483294B2 (en) 2019-10-30
CN1649902A (zh) 2005-08-03
ATE477276T1 (de) 2010-08-15
US7919087B2 (en) 2011-04-05
AU2009243494A1 (en) 2009-12-24
WO2003074567A2 (en) 2003-09-12
JP2010088439A (ja) 2010-04-22
CN102174108B (zh) 2016-06-29
US20100284906A1 (en) 2010-11-11
US20110195023A1 (en) 2011-08-11
US20100266497A1 (en) 2010-10-21
AU2009243494B2 (en) 2012-05-24
JP2006502699A (ja) 2006-01-26
HK1071576A1 (en) 2005-07-22
JP5335651B2 (ja) 2013-11-06
US20100015048A1 (en) 2010-01-21
WO2003074567A3 (en) 2003-12-31
ES2350477T5 (es) 2020-05-06
EP2308898A1 (en) 2011-04-13
DK1483294T3 (da) 2010-11-08
US20080138333A1 (en) 2008-06-12
CA2478012C (en) 2012-06-19
US7772373B2 (en) 2010-08-10
US20080166342A1 (en) 2008-07-10
CA2478012A1 (en) 2003-09-12
EP1483294A2 (en) 2004-12-08
EP1483294B1 (en) 2010-08-11
IL163851A0 (en) 2005-12-18
AU2003215732B2 (en) 2009-12-17
CN1649902B (zh) 2011-04-13
US20110244546A1 (en) 2011-10-06

Similar Documents

Publication Publication Date Title
KR101017732B1 (ko) 내재화 항-ｃｄ74 항체 및 그 이용방법
KR101033196B1 (ko) 항-ｃｄ20 항체 및 그 융합 단백질 및 이들의 이용방법
JP4733635B2 (ja) 抗ｃｄ１９抗体
US7534427B2 (en) Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
AU2012216518B2 (en) Internalizing Anti-CD74 Antibodies and Methods of Use
AU2015201433B2 (en) Internalizing anti-cd74 antibodies and methods of use
HK1071576B (en) Internalizing anti-cd74 antibodies and methods of use

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20040901

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20080303

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20100226

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20100826

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20101130

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20110218

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20110218

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20140206

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20140206

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20150205

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20150205

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20160204

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20160204

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20170209

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20170209

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20180209

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20180209

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20210115

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20230117

Start annual number: 13

End annual number: 13

PC1801 Expiration of term

Termination date: 20230903

Termination category: Expiration of duration